Demographic and baseline characteristics (randomised set)
| First-line triple therapy | Second-line triple therapy | ||
|---|---|---|---|
| Characteristic | VPZ/AMX/CLR (n=329) | LPZ/AMX/CLR (n=321)* | VPZ/AMX/MTZ (n=50)† |
| Age (years) | 55.2±12.3 | 53.9±12.9 | 53.0±11.9 |
| Gender | |||
| Male | 196 (59.6) | 194 (60.4) | 25 (50.0) |
| Female | 133 (40.4) | 127 (39.6) | 25 (50.0) |
| Height (cm) | 163.5±8.8 | 164.8±9.1 | 162.4±9.4 |
| Weight (kg) | 62.2±12.4 | 61.5±11.5 | 60.7±11.2 |
| AMX susceptibility | |||
| Susceptible (MIC≤0.03 μg/mL) | 237 (72.0) | 228 (71.3) | 29 (59.2) |
| Resistant (MIC>0.03 μg/mL) | 72 (21.9) | 73 (22.8) | 20 (40.8) |
| Not applicable | 20 (6.1) | 19 (5.9) | 0 (0.0) |
| CLR susceptibility | |||
| Susceptible (MIC≤0.25 μg/mL) | 203 (61.7) | 178 (55.6) | 6 (12.2) |
| Intermediate (MIC=0.5 μg/mL) | 6 (1.8) | 8 (2.5) | 1 (2.0) |
| Resistant (MIC≥1 μg/mL) | 100 (30.4) | 115 (35.9) | 42 (85.7) |
| Not applicable | 20 (6.1) | 19 (5.9) | 0 (0.0) |
| MTZ susceptibility | |||
| Susceptible (MIC<8 μg/mL) | 283 (86.0) | 276 (86.3) | 45 (91.8) |
| Resistant (MIC≥8 μg/mL) | 26 (7.9) | 25 (7.8) | 4 (8.2) |
| Not applicable | 20 (6.1) | 19 (5.9) | 0 (0.0) |
| CLR dose | |||
| 200 mg twice daily | 168 (51.1) | 164 (51.1) | 24 (48.0) |
| 400 mg twice daily | 161 (48.9) | 157 (48.9) | 26 (52.0) |
| CYP2C19 genotype test | |||
| Extensive metabolisers | 274 (83.3) | 273 (85.0) | 43 (86.0) |
| Poor metabolisers | 55 (16.7) | 48 (15.0) | 7 (14.0) |
Data are expressed as mean±SD or as number of subjects with percentage in parentheses.
*Missing antimicrobial susceptibility testing data (n=1).
†Missing antimicrobial susceptibility testing data (n=1).
AMX, amoxicillin; CLR, clarithromycin; CYP, cytochrome P450; LPZ, lansoprazole; MIC, minimum inhibitory concentration; MTZ, metronidazole; VPZ, vonoprazan.